Orqis(R) Medical Corporation, a
medical products company developing and marketing devices to treat heart
failure, announced that the company's MOMENTUM Trial results were
presented during the Late Breaking Clinical Trials session at the annual
American College of Cardiology (ACC) meeting in Chicago. The MOMENTUM Trial
evaluated the percutaneous Cancion System in patients hospitalized with
heart failure.
Barry Greenberg, M.D., Director, Advanced Heart Failure Treatment
Program, University of California San Diego Medical Center, and National
Principal Investigator for the MOMENTUM Trial, presented, "Efficacy and
Safety of Continuous Aortic Flow Augmentation in Patients Hospitalized with
Acute Decompensated Heart Failure: Results of the MOMENTUM Trial."
"While the MOMENTUM Trial did not meet its primary composite efficacy
endpoint, MOMENTUM is a landmark study demonstrating that the Cancion
System, in combination with conventional medical (drug) treatment,
statistically significantly improved cardiac performance compared with drug
treatment alone," stated Dr. Greenberg. He continued, "There has been very
little progress in identifying effective new approaches for treating
patients with decompensated heart failure and the Cancion System provides
physicians with a needed new treatment option."
Mr. Ken Charhut, President and CEO, Orqis Medical, stated, "MOMENTUM
proved that the Cancion System significantly improves cardiac performance."
He continued, "Orqis' unique aortic flow therapy bridges the gap between
medical management and more invasive procedures without ever touching the
heart." The Cancion System is currently available in markets outside the
U.S.
About Heart Failure
Over 5 million Americans suffer from heart failure, a condition in
which the heart becomes weakened and cannot pump blood efficiently. Heart
failure is caused by coronary artery disease, past myocardial infarctions,
cardiomyopathy and other underlying cardiovascular disorders, and it is
characterized by shortness of breath, functional impairment, and edema. In
the U.S., heart failure results in over 1 million hospitalizations annually
and is responsible for over $33 billion in direct and indirect costs to the
U.S. healthcare system each year.
About Orqis Medical Corporation
Orqis Medical Corporation is a privately held medical device company
that develops and sells minimally invasive devices that improve cardiac
performance through aortic flow therapy. Orqis devices uniquely bridge the
treatment gap between medical management and more invasive procedures
without ever touching the heart. The percutaneous Cancion System has
secured the CE mark. The implantable Exeleras(R) System is in development.
For more information on Orqis Medical, please visit
orqis
Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks
of Orqis Medical Corporation.
Orqis Medical Corporation
orqis